Literature DB >> 11688717

Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold.

S Schlehuber1, A Skerra.   

Abstract

Anticalins comprise a novel class of receptor proteins with predetermined ligand specificities which were engineered using the lipocalin fold. Attractive features of these artificial ligand-binding proteins include their small size and monomeric nature, being composed of a single polypeptide chain. Here we report the construction of a functional fusion protein from two independent anticalins, a so-called duocalin. The gene for the fusion protein was assembled from nucleotide sequences encoding an anticalin with fluorescein specificity on the one hand and an anticalin with digoxigenin specificity on the other. Both engineered lipocalins were previously selected from a random library prepared on the basis of the bilin-binding protein, a natural lipocalin abundant in insects. The corresponding fusion protein was expressed in a secretable form in E. coli cells and isolated from the periplasmic fraction using the Strep-tag method. The major fraction of the purified protein appeared to possess the proper pattern of altogether four disulphide bonds. The ligand-binding behaviour of the fusion protein was investigated both by solid phase ELISA and in fluorescence titration experiments. Our results demonstrate that the novel fusion protein has retained both ligand specificities. Up to now, dimerized ligand-binding proteins were mostly derived from recombinant antibody fragments. Compared with those constructs the duocalins, either with bispecific or with bivalent target recognition properties, should provide useful reagents for various purposes in biotechnology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11688717     DOI: 10.1515/BC.2001.166

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Excited protein states of human tear lipocalin for low- and high-affinity ligand binding revealed by functional AB loop motion.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  Biophys Chem       Date:  2010-04-09       Impact factor: 2.352

Review 2.  Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.

Authors:  Dalal AlDeghaither; Brandon G Smaglo; Louis M Weiner
Journal:  J Clin Pharmacol       Date:  2015-03       Impact factor: 3.126

3.  Ligand binding site of tear lipocalin: contribution of a trigonal cluster of charged residues probed by 8-anilino-1-naphthalenesulfonic acid.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  Biochemistry       Date:  2008-01-08       Impact factor: 3.162

Review 4.  Emerging new therapeutic antibody derivatives for cancer treatment.

Authors:  Shijie Jin; Yanping Sun; Xiao Liang; Xinyu Gu; Jiangtao Ning; Yingchun Xu; Shuqing Chen; Liqiang Pan
Journal:  Signal Transduct Target Ther       Date:  2022-02-07

Review 5.  Anticalin® Proteins as Therapeutic Agents in Human Diseases.

Authors:  Christine Rothe; Arne Skerra
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.